AnaptysBio (ANAB) vs Pacira BioSciences (PCRX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
AnaptysBio (ANAB) has outperformed Pacira BioSciences (PCRX) over the past year, gaining 117.8% versus a gain of 57.5%. Over five years, ANAB leads with a +141.8% price change compared with -31.7% for PCRX. Pacira BioSciences is the larger company by market cap ($1.45 billion vs $1.37 billion), about 1.1 times the size.
On valuation, AnaptysBio trades at a lower forward P/E (9.1x vs 10.5x for Pacira BioSciences).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ANAB | PCRX |
|---|---|---|
| Share price | $45.95 | $36.31 |
| Market cap | $1.37B | $1.45B |
| 1-day change | -0.56% | -0.22% |
| YTD return | +42.98% | +40.30% |
| 1-year return | +117.77% | +57.46% |
| 5-year return | +141.77% | -31.75% |
| P/E ratio (TTM) | — | 103.74 |
| Forward P/E | 9.07 | 10.50 |
| EPS (TTM) | $-0.96 | $0.35 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $726.41M |
| Revenue growth (YoY) | — | +3.63% |
| Net income (latest FY) | — | $7.03M |
| Gross margin | — | 79.39% |
| Operating margin | — | 2.64% |
| Net margin | — | 0.97% |
| 52-week high | $72.36 | $36.46 |
| 52-week low | $20.18 | $18.80 |
| Distance from 52-week high | -36.50% | -0.41% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +89.88% | -17.08% |
| Average volume | 565.82K | 1.03M |
| Shares outstanding | 29.90M | 39.91M |
| Employees | — | 825 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ANAB has outperformed PCRX by 60.3 percentage points over the past year.
About AnaptysBio
ANAB stock →AnaptysBio, Inc. discovers and out-licenses therapeutic bodies in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations
About Pacira BioSciences
PCRX stock →Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States.
Health Care · Biotechnology: Pharmaceutical Preparations · 825 employees
ANAB vs PCRX FAQ
Which is bigger, AnaptysBio or Pacira BioSciences?
Pacira BioSciences (PCRX) is larger, with a market capitalization of $1.45B compared with $1.37B for AnaptysBio (ANAB).
Which stock has performed better over the past year, ANAB or PCRX?
ANAB returned +117.77% over the past 12 months, compared with +57.46% for PCRX (price return, excluding dividends). Past performance does not predict future results.
Are AnaptysBio and Pacira BioSciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.